The Duke-Margolis Center for Health Policy is developing U.S. policy approaches that could provide better economic incentives to antimicrobial developers that successfully bring effective drugs to themarket, providing societal benefit that exceeds the cost of the incentive. Working with a broad-...
Learn about the Duke-Margolis Center's founder, our accomplishments in our first year, and the outstanding faculty and staff who make it all happen!
Selected Peer Reviewed Publications for the calendar year 2016 are listed below:
This is the third in a series of reports from the Planning Board to support the U.S. Food and Drug Administration’s (FDA) work to establish the National Evaluation System for health Technology (NEST). NEST is envisioned as a cooperative network of partners working to use data, advanced...
This white paper explores strategies for a more robust application of clinical pharmacology in drug development and regulatory review. Duke-Margolis staff and a working group of experts provide an overview of the key opportunities stakeholders have to leverage clinical pharmacology tools to...
In recent years, experts in the development and regulation of medical products have explored promising new adaptive clinical trial designs to help speed innovative new therapies to patients in need. This white paper, based on...
